United Therapeutics (NASDAQ:UTHR) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 3 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 2 | 0 | 1 | 0 | 0 |
2M Ago | 0 | 1 | 0 | 0 | 0 |
3M Ago | 1 | 2 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $336.78, a high estimate of $400.00, and a low estimate of $240.00. Observing a 13.18% increase, the current average has risen from the previous average price target of $297.56.
![1721912420_0.png](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240725/45486639-0-65a8e7e689160ba63a0bd0b9ecec06b5.png/big)
Investigating Analyst Ratings: An Elaborate Study
The perception of United Therapeutics by financial experts...
Login or create a forever free account to read this news
Sign up/Log in